Pareta Rajesh A, Farney Alan C, Opara Emmanuel C
Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
Pathobiology. 2013;80(4):194-202. doi: 10.1159/000345873. Epub 2013 May 6.
Islet transplantation has been shown to be a viable treatment option for patients afflicted with type 1 diabetes. However, the lack of availablity of human pancreases and the need to use risky immunosuppressive drugs to prevent transplant rejection remain two major obstacles to the routine use of islet transplantation in diabetic patients. Successful development of a bioartificial pancreas using the approach of microencapsulation with perm-selective coating of islets in hydrogels for graft immunoisolation holds tremendous promise for diabetic patients because it has great potential to overcome these two barriers. In this review article, we will discuss the need for a bioartificial pancreas, provide a detailed description of the microencapsulation process, and review the status of the technology in clinical development. We will also critically review the various factors that will need to be taken into consideration in order to achieve the ultimate goal of routine clinical application.
胰岛移植已被证明是1型糖尿病患者可行的治疗选择。然而,人胰腺的可获得性不足以及需要使用有风险的免疫抑制药物来预防移植排斥反应,仍然是在糖尿病患者中常规使用胰岛移植的两个主要障碍。采用水凝胶中胰岛的选择性渗透涂层微囊化方法成功开发生物人工胰腺,对糖尿病患者具有巨大前景,因为它极有可能克服这两个障碍。在这篇综述文章中,我们将讨论生物人工胰腺的需求,详细描述微囊化过程,并综述该技术在临床开发中的现状。我们还将批判性地审视为实现常规临床应用这一最终目标而需要考虑的各种因素。